MoonLake Immunotherapeutics (MLTX) Operating Leases (2022 - 2026)

MoonLake Immunotherapeutics' Operating Leases history runs 5 years deep, the most recent figure standing at $865000.0 for Q1 2026.

• In Q1 2026, Operating Leases fell 24.26% year-over-year to $865000.0; the TTM figure through Mar 2026 stood at $865000.0 (down 24.26% YoY), while the FY2025 annual figure was $374000.0, down 74.35% from the prior year.
• Operating Leases was $865000.0 for Q1 2026 at MoonLake Immunotherapeutics, up from $374000.0 in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $3.4 million in Q3 2024 to a low of $91081.0 in Q1 2023.
• Historically, Operating Leases has averaged $1.4 million across 5 years, with a median of $1.3 million in 2024.
• The sharpest annual moves came in 2024 and 2025: Operating Leases jumped 2488.35% in 2024, then plunged 74.35% in 2025.
• A 5-year view of Operating Leases shows it stood at $128951.0 in 2022, then surged by 1838.71% to $2.5 million in 2023, then tumbled by 41.68% to $1.5 million in 2024, then slumped by 74.35% to $374000.0 in 2025, then soared by 131.28% to $865000.0 in 2026.
• The last three Operating Leases figures came in at $865000.0 (Q1 2026), $374000.0 (Q4 2025), and $2.0 million (Q3 2025), per Business Quant data.